BCRX
BioCryst Pharmaceuticals Inc. Healthcare - Biotechnology Investor Relations →
BioCryst Pharmaceuticals Inc. (BCRX) closed at $8.99 as of 2026-06-19, trading 11.1% above its 200-week moving average of $8.09. The stock moved further from the line this week, up from 7.2% last week. The 14-week RSI sits at 56, indicating neutral momentum.
Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.18 ratio) is neutral — neither side is clearly dominating.
Over the past 1637 weeks of data, BCRX has crossed below its 200-week moving average 20 times. On average, these episodes lasted 46 weeks. The average one-year return after crossing below was -12.4%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $2.3 billion, BCRX is a mid-cap stock. The company generates a free cash flow yield of 11.6%, which is notably high. The stock trades at -4.1x book value.
Share count has increased 13.4% over three years, indicating dilution.
Over the past 31.4 years, a hypothetical investment of $100 in BCRX would have grown to $156, compared to $2638 for the S&P 500. BCRX has returned 1.4% annualized vs 11.0% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BCRX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BCRX Crosses Below the Line?
Across 20 historical episodes, buying BCRX when it crossed below its 200-week moving average produced an average return of -12.2% after 12 months (median -34.0%), compared to +10.7% for the S&P 500 over the same periods. 21% of those episodes were profitable after one year. After 24 months, the average return was +32.4% vs +18.2% for the index.
Each line shows $100 invested at the moment BCRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices BCRX would reach each dislocation threshold.
Dislocation Price Levels
Prices where BCRX's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-08-03.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $7.05 | Unusually cheap — potential buy zone |
| Value | +1σ | $7.95 | Cheap vs. own history |
| Fair Value | +0σ | $9.12 | Historical mean behavior |
| Expensive | -1σ | $10.69 | Expensive vs. own history |
| Deep Expensive | -2σ | $12.92 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from BCRX's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
BCRX has crossed below its 200-week MA 20 times with an average 1-year return of +-12.4% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 1997 | Jul 1999 | 96 | 42.7% | -27.3% | -6.6% |
| Oct 2000 | Nov 2003 | 160 | 93.4% | -49.4% | +33.8% |
| Nov 2003 | Mar 2004 | 15 | 21.4% | -24.1% | +9.4% |
| Jul 2004 | Jul 2004 | 1 | 1.4% | +38.3% | +87.3% |
| Mar 2005 | Jun 2005 | 12 | 11.6% | +311.4% | +104.8% |
| Mar 2007 | Apr 2007 | 2 | 7.6% | -51.5% | +7.4% |
| Apr 2007 | Aug 2007 | 15 | 23.4% | -56.8% | +3.0% |
| Sep 2007 | Jul 2009 | 96 | 88.9% | -61.5% | +12.7% |
| Dec 2009 | Jan 2010 | 4 | 20.6% | -26.3% | +34.2% |
| Jan 2010 | Mar 2010 | 6 | 7.0% | -37.7% | +31.8% |
| Mar 2010 | Mar 2010 | 2 | 1.4% | -48.9% | +33.6% |
| Jun 2010 | Feb 2012 | 90 | 48.8% | -44.4% | +40.9% |
| Apr 2012 | Jul 2013 | 68 | 75.2% | -61.0% | +106.2% |
| Jan 2016 | Mar 2017 | 60 | 77.4% | -16.2% | +20.5% |
| Apr 2017 | Aug 2018 | 70 | 50.2% | -36.6% | +23.8% |
| Oct 2018 | Oct 2018 | 1 | 1.7% | -60.1% | +32.8% |
| May 2019 | Nov 2020 | 80 | 67.5% | +64.2% | +170.8% |
| Feb 2023 | May 2025 | 114 | 57.9% | -36.1% | +2.3% |
| Jun 2025 | Feb 2026 | 35 | 25.9% | N/A | -4.0% |
| Mar 2026 | Mar 2026 | 1 | 0.4% | N/A | +9.4% |
| Average | 46 | — | +-12.4% | — |
Frequently Asked Questions
Is BCRX below its 200-week moving average?
No. BioCryst Pharmaceuticals Inc. (BCRX) is currently 11.1% above its 200-week moving average of $8.09. It would need to fall to $8.09 to cross below the line.
What is BCRX's 200-week moving average price?
BioCryst Pharmaceuticals Inc.'s 200-week moving average is $8.09 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BCRX drops below its 200-week moving average?
BCRX has crossed below its 200-week moving average 20 times in our data. The average one-year return after these crossings was -12.4%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 46 weeks on average.
Is BCRX a good value right now?
Here's what our data says about BCRX as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 56. Free cash flow yield is 11.6%. Price-to-book is -4.1x. This is not a buy or sell recommendation — always do your own research.
How does BCRX compare to the S&P 500?
Over the past 31.4 years, $100 invested in BCRX would have grown to $156, compared to $2638 for the S&P 500. That's 1.4% annualized vs 11.0% for the index. BCRX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19